Lee’s Pharm acquired Greater China commercialization rights to episil®, a treatment for oral mucositis, from Japan’s Solasia Pharma. The agreement does not include Taiwan nor the cities of Beijing, Shanghai or Guangzhou, which Solasia will retain. episil®, an oral liquid that treats the pain associated with oral mucositis, was developed by Camurus of Sweden. Solasia in-licensed rights to the product for Japan and China in 2015. Financial details of the agreement were not disclosed.
